Amgen Inc

NASDAQ:AMGNUnited States

Nov 8, 2024

Show headlines and story abstract

• AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE, from 4:00PM ET on Friday Nov 08, 2024 by PR Newswire

  4:00PM ET on Friday Nov 08, 2024 by PR Newswire
  Companies Mentioned: AMGN

  Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

• AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE, from 4:00PM ET on Friday Nov 08, 2024 by Dow Jones

  4:00PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: AMGN
  
  AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
  
  PR Newswire
  
  THOUSAND OAKS, Calif., Nov. 8, 2024
  
  THOUSAND OAKS, Calif., Nov. 8, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
  

• Amgen's Chronic Rhinosinusitis Drug Meets Main, Secondary Goals in Phase 3 Trial, from 4:54AM ET on Friday Nov 08, 2024 by MT Newswires

  4:54AM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: AMGN, AZN
  04:54 AM EST, 11/08/2024 (MT Newswires) -- Amgen (AMGN) said late Thursday that its drug, Tezspire, which it co-developed with AstraZeneca (AZN) to treat patients with chronic rhinosinusitis with nasal polyps, met primary goals in a phase 3 study. T...

• TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS, from 2:00AM ET on Friday Nov 08, 2024 by PR Newswire

  2:00AM ET on Friday Nov 08, 2024 by PR Newswire
  Companies Mentioned: AMGN

  Statistically Significant Reduction in Nasal Polyp Size, Nasal Congestion Compared to Placebo

  Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial demonstrated patients treated with TEZSPIRE(R) (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. The safety profile and tolerability ofTEZSPIREin the trial were consistent with the known profile of the medicine.